Objectives We evaluated several flavonoid combinations for synergy in the inhibition of proinflammatory mediator synthesis in the RAW 264.7 cellular model of inflammation. Methods The inhibitory effect of chrysin, kaempferol, morin, silibinin, quercetin, diosmin and hesperidin upon nitric oxide (NO), prostaglandin E 2 (PGE 2 ) and tumour necrosis factor-a (TNF-a) secretion from the LPS-induced RAW 264.7 monocytic macrophage was assessed and IC 50 values obtained. Flavonoids that showed reasonable inhibitory effects in at least two out of the three assays were combined in a series of fixed IC 50 ratios and reassessed for inhibition of NO, PGE 2 and TNF-a. Doseresponse curves were generated and interactions were analysed using isobolographic analysis.
Introduction
The flavonoids comprise a very large group of compounds found in many herbal preparations and have been shown to possess potent anti-inflammatory effects in both cellular and animal models of inflammation [1] . Herbal practitioners have always believed that effective phytomedicines on the drug market acquire their therapeutic efficacy via synergistic interactions between the components of individual or mixtures of herbs. The use of drug combinations is not confined to herbal products alone, and, for example, cancer chemotherapy, the treatment of HIV, neurological disorders and hypertension routinely employ drug combinations consisting of two or more substances [2] .
The combinatorial use of drugs aims to induce a response upon multiple targets, multiple subpopulations, or multiple diseases simultaneously. Furthermore, combinatorial use of multiple drugs with dissimilar mechanisms or modes of action may also direct the effect against a single target or disease with a more effective therapeutic outcome. The possible favourable outcomes for synergism include (1) increased therapeutic efficacy, (2) decreased dosage and toxicity while increasing or maintaining the same efficacy, (3) reduction of the development of drug resistance, and (4) provision of selective synergism against target (efficacy synergism) versus host (toxicity antagonism). Indeed drug combinations have been widely used and have become the leading choice for treating chronic debilitating diseases [3] .
Most pharmacological studies with anti-inflammatory flavonoids have described drug-like effects in cellular in vitro systems. Studies in man have evaluated flavonoids for prophylaxis of cancer [4] , cardiovascular [5] , gastrointestinal [6] , and neurological [7] disease. These studies are mostly concerned with effect of dietary flavonoid consumption and prevention of disease. However, it is interesting to note that a micronized purified flavonoid fraction containing 90% diosmin and 10% hesperidin (Daflon 500 TM ) has been used successfully for the therapeutic management of chronic venous disease and haemorrhoidal disease [8] .
Very few studies have shown that flavonoids can act synergistically when combined with other drugs. For instance, some flavones have weak antibacterial effects on methicillin-resistant Staphylococcus aureus (MRSA), but at sub-MIC concentrations they greatly increase the susceptibility of MRSA to b-lactam antibiotics [9] . In the area of cancer therapeutics silibinin, a flavanone, has shown synergistic antiproliferative effects upon normal and drugresistant ovarian and breast tumour cell lines when combined with cisplatin and doxorubicin [10] . A study on LDL oxidation showed that rutin, a quercetin-3-rutinoside, caused a synergistic prevention of LDL oxidation when combined with ascorbate and c-terpinene [11] . Several studies have described effects of flavonoids upon the central nervous system [12] [13] [14] . Several flavonoids possess a selective and relatively mild affinity for the central benzodiazepine binding site in the GABA A receptor. Furthermore, synergy studies have shown that several flavonoids such as methylapigenin and hesperidin cause synergistic anxiolytic effects when combined with diazepam [15] .
To our knowledge, isobolographic analysis of synergistic effects of flavonoid combinations upon proinflammatory mediator secretion have not been reported. Although one study [16] showed that genistein and epigallocatechin gallate (EGCG) enhanced effects of several NSAIDs, the analysis of the data did not employ appropriate isobolographic methodology. In this communication we show that the potency of several flavonoids can be enhanced following combinatorial treatment of monocytic macrophage cells induced to synthesize excess proinflammatory mediators. In addition to the objective of enhancing potency while reducing toxicity, we also took into account the cost of the flavonoids used when devising our objectives. The cost is usually determined by the complexity of the synthetic procedure and cost of starting material. We realized that potent anti-inflammatory flavonoids such as apigenin, luteolin, and EGCG are extremely costly and therefore we focused our approach upon flavonoids that may exert equivalent, if not better potencies when combined, with reduced costs.
This communication describes an isobolographic approach to the study of combinatorial treatment of antiinflammatory flavonoids in cellular assays of inflammation. We demonstrate several flavonoid combinations that cause a significantly high degree of synergy in their inhibition of proinflammatory mediator secretion. These findings strengthen claims by herbalists pertaining to the synergism of components of herbal cocktails to induce a therapeutic effect and the rationale for multimodal therapeutics in experimental and clinical medicine. Additionally, these findings open further avenues of research into combinatorial therapeutics of inflammatory-related diseases and the pharmacology of flavonoid synergy.
Methods

Reagents and kits
Lipopolyssacharide (LPS from Escherichia coli serotype 055:B5), NS-398, sulfanilamide, naphthylenediamine, dexamethasone, 3-[4,5-Dimethyl-2-thiazolyl]-2,5-diphenyl tetrazolium bromide (MTT) and N-nitro-L-arginine methyl ester (L-NAME), were purchased from Sigma-Aldrich (St Louis, MO, USA). Antibiotics (5,000 U/ml penicillin and 5,000 lg/ml streptomycin), foetal bovine serum (FBS) and Dulbecco's Modified Eagle Medium (DMEM) were purchased from Hyclone (UT, USA). TNF-a immunoassay kit was purchased from BD Pharmingen (San Diego, CA, USA). Prostaglandin E 2 enzyme immunoassay kit was purchased from Cayman Chemicals, USA. Dimethyl sulfoxide (DMSO) was purchased from Amresco (Solon, OH, USA).
Flavonoids
Chrysin, kaempferol, morin, silibinin, hesperidin, diosmin, and quercetin were purchased from Sigma-Aldrich (St Louis, MO, USA). Figure 1 shows the structure of these flavonoids. These compounds were dissolved in 100% DMSO as a stock of 0. Cell culture and induction of mediator secretion
The murine monocytic macrophage cell line (RAW 264.7) was purchased from American Type Culture Collection (Manassas, VA, USA). RAW 264.7 cells were maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin, 100 lg/mL streptomycin, 4.5 g/L glucose, 1 mM sodium pyruvate, 2 mM L-glutamine, and 10 mM HEPES. Cells were maintained at 37°C, with 5% CO 2 in fully humidified air and split 3 times a week. Cells at a confluency of 80-90% were scraped out and centrifuged at 120 g at 4°C for 7 min. The concentration was adjusted to (1 9 10 6 cells/mL) and cell viability was always more than 90%, as determined by Trypan blue dye exclusion. A total of 50 lL of cell suspension was dispensed into wells of a tissue-culture-grade 96-well microplate (1 9 10 5 cells/ well) and incubated for 2 h at 37°C, 5% CO 2 to attach the cells. Blank wells with media alone were included. After 2 h, unattached cells were gently discarded. Attached cells were then induced with 10 lg/mL of LPS in the presence or absence of the compounds at a final volume of 100 lL/ well. Untreated cells and drug controls were stimulated with LPS and also had the same amount of DMSO in culture medium. Cells were then incubated for 18 h at 37°C in 5% CO 2 .
Cell viability
Cell viability was assessed following the removal of spent media by addition of MTT. Briefly, 100 lL of DMEM containing 5% FBS was added to each well followed by 20 lL of MTT (5 mg/mL in PBS). The formazan crystals were dissolved with 100 lL of 100% DMSO per well after 3 h. The absorbance was measured at k 570 nm with a microplate reader (UVM 340, ASYS Hitech GmbH, Austria) by using a reference wavelength of 650 nm. Cell viability was determined as the percentage of untreated induced cells.
Determination of nitrite secretion
The concentration of nitrite (NO 2 -) in spent media was determined by the Griess reaction. Briefly, an equal volume of the Griess reagent (1% sulfanilamide/0.1% naphtylethyenediamine dihydrochloride in 2.5% H 3 PO 4 ) was mixed with spent media and colour development was assessed at k 550 nm with a microplate reader (UVM 340, ASYS Hitech GmbH, Austria). Fresh culture medium was used as the blank in all the experiments. The concentration of nitrite in the samples was calculated from a sodium nitrite standard curve (0-100 lmol/L). L-NAME was used at 250 lM as a drug control. Dose-response curves and IC 50 values were calculated using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, California, USA, http://www.graphpad.com). All experiments were performed in triplicate.
Determination of PGE 2 secretion
Spent media was collected and stored at -30°C prior to assay. PGE 2 concentrations were determined with an enzyme immunoassay kit (Cayman Chemicals, Ann Arbor, MI, USA; Cat no: 514010) according to the manufacturer's instructions. NS-398 was used at 50 lM as a drug control. Dose-response curves and IC 50 values were calculated using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, California, USA, http:// www.graphpad.com). All experiments were performed in triplicate.
Determination of TNF-a secretion Spent media was collected and stored at -30°C prior to determination of cytokine concentrations. TNF-a concentrations were assayed with an enzyme immunoassay kit (BD Pharmingen, San Diego, CA, USA, Cat No. 555268) according to the manufacturer's instructions. Dexamethasone was used at 10 lM as a drug control. Dose-response curves and IC 50 values were calculated using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, California, USA, http://www.graphpad.com). All experiments were performed in triplicate.
Isobolographic analysis
The interaction of the various flavonoids was evaluated by the simultaneous administration of fixed proportions of flavonoids, and performing an isobolographic analysis for the different combinations, as described by [17] . The isobologram was constructed by connecting the IC 50 of the corresponding flavonoids plotted on the abscissa and ordinate to obtain the additivity line. For each flavonoid mixture, the IC 50 and its associated 95% confidence intervals were determined by linear regression analysis of the log dose-response curve (five experiments in triplicate at each of nine doses) and compared by a t-test to a theoretical additive IC 50 obtained from the calculation: IC 50 add = IC 50 flavo1 /(P1 ? RÁP2), where R is the potency ratio of the flavonoid 1 alone, P1 is the proportion of flavonoid 1 and P2 is the proportion of flavonoid 2 in the total mixture. In the present study, fixed-ratio proportions were selected by first combining the IC 50 of each compound and then constructing a dose-response curve in which IC 50 fractions (following twofold serial dilutions) of flavonoid combinations were used; in the equation above, IC 50 add is the total dose and the variance of IC 50 add was calculated from the fraction of the IC 50 's in the combination as: Var IC 50 add = (fraction) 2 Á Var IC 50 flavo1 ? (fraction) 2 Á Var IC 50 flavo2 [18] . From these variances, confidence limits are calculated and resolved according to the ratio of the individual drugs in the combination. Supra-additivity or synergism is determined as the effect of a flavonoid combination which is higher and statistically different (IC 50 significantly lower) than the theoretical calculated equieffect of a flavonoid combination with the same proportions. When the flavonoid combination gives an experimental IC 50 not statistically different from the theoretically calculated IC 50 , the combination has an additive effect and additivity means that each constituent contributes to the effect in accord with its own potency and the less potent flavonoid is acting as though it is merely a diluted form of the other [19] .
Statistical analysis
Results are presented as IC 50 values with 95% confidence limits. Student's t test for independent means was used to assess statistical significance between observed and theoretical IC 50 s.
Results
Cytotoxicity
All compounds (single and in combination) except for chrysin had no cytotoxic effect upon cells. Chrysin reduced viability to 72% at the highest dose tested (200 lM), however all other doses were not toxic. Generally cell viability was always above 90%.
Selection of flavonoids for combinatorial experiments
In order to determine the doses to be used in combinatorial treatments, we assayed single flavonoids for inhibitory effects upon NO, PGE 2 , and TNF-a secretion. Table 1 summarizes the IC 50 values of each flavonoid following dose-response analysis. All flavonoids produced doseresponse curves, however, several were weak and failed to cause inhibitory effects of more than 50% in some assays. In particular, hesperidin, diosmin and quercetin were the weakest and the IC 50 could not be calculated in several assays. Flavonoids that were poor inhibitors of two or more mediators were not included in combinatorial experiments. Therefore, we selected four of the seven flavonoids, namely chrysin, kaempferol, morin, and silibinin for combination studies.
Synergy and additivity upon NO inhibition Figure 2 shows the various dose response curves generated following treatment of induced RAW 264.7 cells with combinations of flavonoids. The most potent response was observed when kaempferol was mixed with chrysin. This combination reduced the IC 50 to 2.2 lM. Other combinations reduced the IC 50 except for morin/silibinin, in which the combined IC 50 of 53.7 lM was close to the IC 50 of both compounds (44.85 and 48.01 lM, respectively). Isobolograms are shown in Fig 3. All combinations except morin/ silibinin showed a significant (P \ 0.001) synergistic effect. Morin/silibinin was additive.
Synergy and additivity upon PGE 2 inhibition Figure 4 shows the various dose response curves generated following treatment of induced RAW 264.7 cells with Synergy and additivity upon TNF-a inhibition Figure 6 shows the various dose response curves generated following treatment of induced RAW 264.7 cells with combinations of flavonoids. Since morin was a weak inhibitor of TNF-a secretion, in which the IC 50 could not be determined, this compound was not included in these experiments. Combinations with kaempferol were potent and reduced the IC 50 far below the IC 50 values of the compounds when used alone. However, chrysin/silibinin were only additive in their effect. Isobolograms are shown in Fig 7. Combinations with kaempferol showed a significant synergistic effect, however, chrysin/silibinin were only additive.
Discussion
Investigations into the effect of dietary flavonoids upon inflammation have demonstrated significant anti-inflammatory effects due to the inhibition of major proinflammatory mediators. We notice that the majority of reports that show inhibitory effects of flavonoids in similar in vitro systems to ours, employed a pretreatment approach and others used different cell lines of similar or different species. Whether this approach was chosen to mimic preventive effects in complete biological systems is not clear, however, we have noticed that this approach has provided data that conflicts with ours. For instance, in human mononuclear leucocytes it was shown that silibinin inhibited PGE 2 secretion with an IC 50 of 43 lM [20] whereas in our assay the IC 50 was 5.98 lM, a sevenfold difference. Studies on quercetin showed that it strongly inhibits NO and TNF-a secretion via inhibition of nuclear factor-jB (NF-jB) and mitogen-activated protein kinase (MAPK) pathways [21, 22] . Conversely, we did not find quercetin to be a good choice for combinatorial treatment since its inhibition of NO was moderate and failed to give a strong inhibition of TNF-a and PGE 2 secretion and calculable IC 50 . We showed that morin and hesperidin produced reasonable inhibition of PGE 2 in this report whereas [23] showed no inhibitory effect upon PGE 2 secretion by rat peritoneal macrophages that received treatment prior to LPS induction, however, our IC 50 values for chrysin, kaempferol, and quercetin were not far off from theirs. Furthermore, kaempferol and morin were poor inhibitors of NO secretion from LPS-induced J774 cells [24] whereas we found both compounds to be strong inhibitors of NO. An example of variation due to cell line and/or stimulus is observed in the effect of both kaempferol and quercetin in which both compounds had no effect upon NF-jB translocation and DNA-binding activity in PMA-induced human mast cells [25] whereas both flavonoids inhibited NF-jB binding when applied to HUVEC lines induced by a mixture of cytokines [26] . It is obviously clear that cell type, species and assay system employed significantly affect the inhibition of proinflammatory mediators by flavonoid compounds. Many flavonoids act via inhibition of major proinflammatory signaling pathways and therefore pretreatment of cells will block signal transduction prior to the addition of inflammatory stimuli. It is important that studies aimed at evaluating potential therapeutic use of flavonoids should either treat cells simultaneously or following application of the inflammatory stimuli. This is critical since certain flavonoids with potent preventive activity may be weak inhibitors of mediator synthesis/secretion when used therapeutically. The spectrum of synergism over the assay systems employed varied between mediators assayed but in general showed that kaempferol/chrysin combinations were highly synergistic in all assays. Morin/chrysin and morin/kaempferol combinations were also strongly synergistic in their inhibition of PGE 2 . The explanation as to why these synergisms occur remains obscure, however, existing information regarding the precise action of these flavonoids allows for speculation and generates more questions for further work. It is possible that several combinations may act upon different pathways which converge to activate mediator synthesis. For instance, in the case of chrysin/kaempferol the lack of inhibitory effect of chrysin upon NF-jB activation [27] may have been taken over by kaempferol [28] , furthermore chrysin inhibits interferon regulatory factor 1 (IRF-1) [27] and thus may act to reinforce a stronger inhibitory response. Additionally kaempferol strongly inhibits extracellularregulated kinase 1/2 (ERK 1/2) and c-Jun NH 2 -terminal kinase (JNK) [7] which could further enhance the inhibitory effect. Indeed similar possibilities may occur in other combinations albeit via varying disruptive mechanisms. In some cases, it can be argued as to why two compounds with similar modes of action, albeit with different degrees of potency, synergise when combined. Could yet unidentified targets be able to clarify this enigma? Indeed, in the case of the role of antioxidants (including several flavonoids) upon disruption of the NFjB, pathway it has been suggested that as NF-jB pathways are more defined and more potential points of regulation described, that many antioxidants purported to inhibit NF-jB due to effects on reactive oxygen species (ROS) actually may have novel targets that are not a direct antioxidant effect. Rather, they may chemically modify proteins or activate kinases or phosphatases that modulate inhibitors of jB kinase (IKK) activity [29] . Similar speculations can be projected to other proinflammatory pathways such as MAPK, signal transducer and activator of transcription (STAT) and phosphoinositide-3-kinase (PI3K). Other questions that arise include: do the flavonoids work on a common target in a more intense manner? Do the compounds interact chemically to form a new ligand? Is there a common denominator in the subclasses that promotes synergy upon combination? These are questions that need be addressed by the employment of medicinal chemistry and molecular pharmacology tools.
Since we have only evaluated synergy based on secreted mediators we can only speculate that the effects are due to combined inhibition of complex biosynthetic pathways, however, it should be noted that cellular secretory mechanisms may also be affected. In fact, we have not found any work that has described the effects of flavonoids on the secretory mechanism of proinflammatory mediators. It is possible that flavonoids not only inhibit mediator synthesis but also secretory mechanisms when combined. Experiments are underway to address this possibility. In conclusion, we have demonstrated that certain flavonoids do indeed act in a drug-like fashion in which combinations can yield significant synergistic effects in the inhibition of the secretion of major proinflammatory mediators. At present we can only speculate as to the reasons why certain combinations are synergistic, since the complexity of compound combinations in a cellular system complicates an explanation of the actual mechanism. Furthermore, the relatively modest and conflicting literature regarding flavonoid effects in cellular models of inflammation limit an in-depth mechanistic explanation. In view of this, further work is envisaged in the area of molecular pharmacology in order to unravel the exact mechanism for synergy amongst flavonoids. 
